A new levodopa product could improve the treatment of advanced Parkinson's patients
 

Orion Corporation presented promising Phase II data for new Parkinson's disease drug at AAN Annual Meeting

A new levodopa product (ODM-101) developed by Orion Corporation could improve the treatment of advanced Parkinson's disease patients. According to a Phase II study, presented yesterday at American Academy of Neurology's Annual Meeting in San Diego, ODM-101 significantly decreased daily OFF-time without increasing ON-time with troublesome dyskinesias compared to reference product Stalevo®, which is an established standard medication for advanced Parkinson's patients experiencing so-called end-of-dose wearing off symptoms associated with levodopa therapy

http://www.orion.fi/en/News-and-medi...rchive/2013/3/